Gabriele Grecchi

CEO at CaSRevolution

Speaker

CaSRevolution is a biotech company developing a first-in-class therapeutic approach for Alzheimer’s disease. Our innovation targets the Calcium Sensing Receptor (CaSR), a key trigger of the neurotoxic cascade initiated by Abeta oligomers. By blocking CaSR with proprietary Negative Allosteric Modulators, we aim to halt amyloid accumulation, tau hyperphosphorylation, and neuroinflammation, addressing Alzheimer’s at its root cause.